Rare diseases imatinib mesylate Continuing PBS authority application Supporting information form (PB108)

For continuing Pharmaceutical Benefits Scheme (PBS) subsidised treatment of patients with Dermatofibrosarcoma protuberans, Hypereosinophilic syndrome or chronic eosinophilic leukaemia, Platelet-DeriveGrowth Factor Receptor (PDGFR) B fusion gene-positive myelodysplastic or myeloproliferative disorder, Aggressive systemic mastocytosis with eosinophilia.

 

Page last updated: 13 July 2016

This information was printed Thursday 29 September 2016 from humanservices.gov.au/health-professionals/forms/pb108 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.